MGMT and glioblastoma: Notably, our mechanistic insights corroborate the clinical efficacy of our recently completed phase II clinical trial [37], which integrates CPZ into the adjuvant phase of the standard first-line treatment regimen for newly diagnosed GBM patients with an unmethylated MGMT gene promoter.